{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:47:02Z","timestamp":1791838022544,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00373"],"award-info":[{"award-number":["PI24\/00373"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cmi.2026.09.025","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:23:41Z","timestamp":1790576621000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro activity of rezafungin against bloodstream and intra-abdominal Candida isolates: a large EUCAST-based study"],"prefix":"10.1016","author":[{"given":"Pilar","family":"Escribano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Moraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Burillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Reigadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.09.025_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiotics"},{"key":"10.1016\/j.cmi.2026.09.025_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae702","article-title":"Activity of rezafungin against echinocandin non-wild type Candida glabrata clinical isolates from a Global Surveillance Program","volume":"12","author":"Castanheira","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.025_bib4","series-title":"Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. Version 6.1","author":"EUCAST","year":"2026"},{"key":"10.1016\/j.cmi.2026.09.025_bib5","series-title":"Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST Definitive Document E.Def 7.4.EUCAST","author":"Guinea","year":"2023"},{"key":"10.1016\/j.cmi.2026.09.025_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/dkac373","article-title":"Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin","volume":"78","author":"Arendrup","year":"2023","journal-title":"J Antimicrob. Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00986-23","article-title":"Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): Fluconazole-resistant C. parapsilosis spreading has gained traction in 2022","volume":"67","author":"D\u00edaz-Garc\u00eda","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib8","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1093\/jac\/dkac288","article-title":"Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: Emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris","volume":"77","author":"D\u00edaz-Garc\u00eda","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00710-22","article-title":"Evidence of fluconazole-resistant Candida parapsilosis genotypes spreading across hospitals located in Madrid, Spain and Harboring the Y132F ERG11p Substitution","volume":"66","author":"D\u00edaz-Garc\u00eda","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01827-20","article-title":"Monitoring the epidemiology and antifungal resistance of yeasts causing fungemia in a tertiary care hospital in Madrid, Spain: Any relevant changes in the last 13 years?","volume":"65","author":"D\u00edaz-Garc\u00eda","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad072","article-title":"Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity","volume":"61","author":"D\u00edaz-Garc\u00eda","year":"2023","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2026.09.025_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/JCM.00118-16","article-title":"Evaluation of fluorescent capillary electrophoresis for rapid identification of Candida fungal infections","volume":"54","author":"Obru\u010dov\u00e1","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.09.025_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13706","article-title":"Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution","volume":"67","author":"Mesquida","year":"2024","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.09.025_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01542-16","article-title":"In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in Candida glabrata isolates","volume":"61","author":"Bordallo-Cardona","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/mmy\/myx124","article-title":"Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata","volume":"56","author":"Bordallo-Cardona","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2026.09.025_bib16","article-title":"Mutant prevention concentration and mutant selection window of micafungin and anidulafungin in clinical Candida glabrata isolates","volume":"62","author":"\u00c1ngeles Bordallo-Cardona","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib17","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: An initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.025_bib18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.09.025_bib19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.09.025_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/myc.70114","article-title":"Rezafungin utilisation in real life-FungiScope results from Europe and the United States","volume":"68","author":"Reinhold","year":"2025","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.09.025_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00099-20","article-title":"Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018)","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"65","key":"10.1016\/j.cmi.2026.09.025_bib23","article-title":"Antifungal susceptibility testing identifies the abdominal cavity as a source of Candida glabrata-resistant isolates","volume":"7","author":"D\u00edaz-Garc\u00eda","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.025_bib24","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1590\/s1678-9946202668020","article-title":"Rezafungin in fluconazole-resistant and refractory candidiasis: The first Brazilian experience","volume":"68","author":"Kruschewsky","year":"2026","journal-title":"Rev Inst Med Trop Sao Paulo"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:02:59Z","timestamp":1791835379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26005410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S1198743X26005410"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.025","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of rezafungin against bloodstream and intra-abdominal Candida isolates: a large EUCAST-based study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}